Overview

Weaning of Immunosuppression in Nephritis of Lupus

Status:
Active, not recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
The investigators wish to evaluate the discontinuation of maintenance immunosuppressive treatment after 2 years in patients with stable remission after a proliferative lupus nephritis. The patients will be continuing their treatment with hydroxychloroquine, possibly associated with low dose corticosteroids.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Treatments:
Azathioprine
Immunosuppressive Agents
Mycophenolate mofetil
Mycophenolic Acid